Some Types of Prostate Cancer May Not be as Aggressive as Originally Thought
Researchers at the UCLA Jonsson Comprehensive Cancer Center analyze gene-expression patterns in the most aggressive prostate cancer grade group—known as Gleason grade group 5—and found that this grade of cancer can actually be subdivided into four subtypes with distinct differences.
Marvels in Medicine: Dr. Karlan on Breaking Down Gender Barriers in Gynecologic Oncology
May 28th 2020In our exclusive interview, Dr. Karlan shares the rewarding moments and challenges she has encountered in the cancer space as a female oncologist, pivotal research she has been spearheaded that has lasting impacts on the field, and other developments in gynecologic cancers that are poised to change the landscape forever.
Chasing a Cure for GBM: Investigators Test Multiple Regimens in Novel Trial
May 14th 2020Investigators of the first global adaptive phase 2/3 GBM Adaptive Global Innovative Learning Environment platform trial are implementing a multiarm, 2-stage approach to concurrently evaluate single-agent and combination regimens in glioblastoma.
Chasing a Cure for GBM: Investigators Test Multiple Regimens in Novel Trial
May 14th 2020Investigators of the first global adaptive phase 2/3 GBM Adaptive Global Innovative Learning Environment platform trial are implementing a multiarm, 2-stage approach to concurrently evaluate single-agent and combination regimens in glioblastoma.
New Treatment Extends Lives of People With Most Common Type of Liver Cancer
For the first time in over a decade, scientists have identified a first-line treatment that significantly improves survival for people with hepatocellular carcinoma, the most common type of liver cancer.
New Therapeutic Era Sparks Fresh Questions About Nephrectomy in RCC
Although fewer patients are undergoing cytoreductive nephrectomy as systemic treatments for renal cell carcinoma improve, the modality still has a vital role to play in the treatment paradigm—even in the modern age of immune checkpoint inhibitors.
Dr. Goldman on the Use of Immunotherapy in Oncogene-Driven NSCLC
March 25th 2020Jonathan W. Goldman, MD, health sciences clinical instructor, Department of Medicine, and Hematology/Oncology member, Jonsson Comprehensive Cancer Center Signal Transduction and Therapeutics Program, UCLA, discusses the use of immunotherapy in patients with oncogene-driven non–small cell lung cancer (NSCLC).
Dr. Hurvitz on Reducing Potential Exposure to COVID-19
March 23rd 2020Sara A. Hurvitz, MD, associate professor at the David Geffen School of Medicine, University of California, Los Angeles (UCLA) medical director of the Jonsson Comprehensive Cancer Center Clinical Research Unit, co-director of the Santa Monica-UCLA Outpatient Oncology Practices, and director, Breast Cancer Clinical Trials Program, UCLA, discusses the steps that can be taken to reduce potential exposure to coronavirus disease 2019 (COVID-19).
Dr. Hurvitz on the Evolution of Treatment in Metastatic HER2+ Breast Cancer
January 17th 2020Sara A. Hurvitz, MD, associate professor at the David Geffen School of Medicine, University of California, Los Angeles (UCLA) medical director of the Jonsson Comprehensive Cancer Center Clinical Research Unit, co-director of the Santa Monica-UCLA Outpatient Oncology Practices, and director, Breast Cancer Clinical Trials Program, UCLA, discusses the evolution of treatment in metastatic HER2-positive breast cancer.
Dr. Hurvitz on the Findings of DESTINY-Breast01 in HER2+ Metastatic Breast Cancer
January 8th 2020Sarah A. Hurvitz, MD, medical oncologist, medical director, Clinical Research Unit for University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the findings in the DESTINY-Breast01 trial of patients with HER2-positive metastatic breast cancer.
Dr. Finn on the Rationale for the Phase III KEYNOTE-240 Trial in HCC
September 25th 2019Richard S. Finn, MD, professor of clinical medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles (UCLA), and Director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center at UCLA, discusses the rationale for the phase III KEYNOTE-240 trial in hepatocellular carcinoma (HCC).
Dr. Hurvitz on Toxicity Associated With Neratinib in HER2+ Breast Cancer
March 26th 2019Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses toxicity associated with neratinib in the treatment of patients with HER2-positive breast cancer.
Dr. Hurvitz on Standards of Care in HER2+ Breast Cancer
March 14th 2019Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the first- and second-line standards of care in HER2-positive breast cancer.